Skip to main content
Premium Trial:

Request an Annual Quote

Genaissance Hopes to Pocket $6M In Private Stock Placement

NEW YORK, Nov. 19 (GenomeWeb News) -  Genaissance Pharmaceuticals expects to pocket $6 million in a private placement of 3.55 million shares of newly issued common stock, and warrants for another 3.55 million shares to undisclosed institutional investors and other accredited investors, the firm said today.

 

The NEw Haven, Conn.-based phramacogenomics company said that it plans to use the proceeds for general corporate purposes, including the repayment of debt.

 

The private placement, which the company said it expects to close this afternoon, comes after announcing earlier this week a layoff of 10 percent of its workforce in an attempt to reach break even from operations.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.